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Abstract: Lipid-based nanoparticles (NPs) with a small amount of surface-chelated nickel
(Ni-NPs) were developed to easily formulate the human immunodeficiency virus (HIV) his-tagged
Tat (his-Tat) protein, as well as to formulate and co-deliver two HIV antigens (his-p24 and
his-Nef) on one particle. Female BALB/c mice were immunized by subcutaneous injection with
his-Tat/Ni-NP formulation (1.5 µg his-Tat/mouse) and control formulations on day 0 and 14.
The day 28 anti-Tat specific immunoglobulin G titer with his-Tat/Ni-NPs was significantly
greater than that with Alum/his-Tat. Furthermore, splenocytes from his-Tat/Ni-NP-immunized
mice secreted significantly higher IFN-γ than those from mice immunized with Alum/his-Tat.
Although Ni-NPs did not show better adjuvant activity than Tat-coated anionic NPs made
with sodium dodecyl sulfate (SDS/NPs), they were less toxic than SDS/NPs. The initial results
indicated that co-immunization of mice using his-p24/his-Nef/Ni-NP induced greater antibody
response compared to using Alum/his-p24/his-Nef. Co-delivery of two antigens using Ni-NPs
also increased the immunogenicity of individual antigens compared to delivery of a single
antigen by Ni-NPs. In conclusion, Ni-NPs are an efficient delivery system for HIV vaccines
including both single antigen delivery and multiple antigen co-delivery.
Keywords: nanoparticle, nickel, HIV, antigen co-delivery, vaccine

Introduction
A protein-based vaccine can induce both antibody responses and T-cell responses
including CTL cytotoxic T lymphocytes (CTL) in the immunized host. Furthermore,
a protein contains multiple epitopes including T-helper (Th) epitopes, which play a
key role in T-cell immunity, and potentiate CD8+ T-cell responses during priming
and/or memory generation.1,2 The utility of adjuvants to enhance immune responses
to protein-based vaccines is widely recognized.3,4 Specifically related to a potential
human immunodeficiency virus (HIV) vaccine, it is critical to design and develop a
vaccine that induces both neutralizing antibody and CTL activity, both of which have
been shown to be essential for prevention and treatment of this disease.5,6
One direction of adjuvant design is to utilize particulate systems including
liposomes,7,8 and other micro- and nanoparticles (NPs)9 to deliver antigens. Our laboratory has reported on the preparation of lipid-based NPs from oil-in-water microemulsion
precursors and on the use of these NPs for enhancing immune responses to protein based
vaccines.10,11 These NPs are approximately 100 nm in size and have the advantage of
being prepared in a single step, one-vessel, process. It is also relatively easy to modify
the physical characteristics of the particles by using appropriate charged surfactants.
Moreover, the oil phase for preparation of these NPs is comprised of cetyl alcohol
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and polysorbate 60, both of which are found in several
pharmaceutical products and are biocompatible.12 In previous studies, the antigens were simply coated on oppositely
charged (either cationic or anionic) nanoparticles wherein
it is possible that some dissociation of the coated protein
from the particle may occur in vivo, resulting in a decreased
accumulation in antigen-presenting cells (APCs). In addition,
the strong ionic surfactants for making the cationic or anionic
NPs may be toxic to cells. To solve these problems, lipid
NPs decorated with a small amount of accessible nickel on
the surface were developed and this system led to enhanced
immune responses.13 In these previous studies, the optimal
binding of the his-tagged proteins (GFP or Gag p24) to
Ni-NPs was about 1:33 w/w (protein-to-oil phase ratio) and
was independent of the size and charge of the his-tagged
protein. Apparently, the interaction between chelated nickel
and the short sequence of histidine residues increased the
delivery efficiency of the protein antigen to APCs.
Multivalent vaccines containing several antigens from
different pathogens in one single formulation are commercially available for vaccinating against diphtheria, tetanus,
pertussis, polio, hepatitis B and Haemophilus influenzae
type B.14,15 Multivalent vaccines not only have significant
cost advantages but also have potential to induce synergistic
effects between the antigens, since CD4 T helper epitopes in
one antigen may enhance B- and T-cell responses induced
by other antigens.2 Thus, ideally, a viable vaccine delivery
system should be able to deliver multiple antigens. Recently,
Lamalle-Bernard and colleagues developed multivalent
vaccines based on anionic polylactic acid (PLA) NPs
for co-delivery of HIV p24 and gp120 proteins and they
showed that the NPs preserved antigenicity and immunogenicity of p24 and gp120.16
The HIV gag gene encodes for four major Gag proteins
in the mature virus.17 Gag proteins are currently under
investigation as potential candidates for the HIV vaccines.
Of these four proteins, the Gag p24 protein has been shown
to be the most conserved among the different HIV subtypes
and many groups have also identified Gag p24 as the target
of Gag-specific cellular responses.18,19 More importantly,
a recent study of HIV-infected patients highlighted the
significance of strong Gag p24-specific cellular responses
in controlling viral replication and CD4+ T cell counts.20
Thus, these features make the HIV-1 Gag p24 protein an
attractive and relevant choice for inclusion in a multivalent
HIV vaccine.
HIV-1 Nef is an early-expressed regulatory protein which
plays an important role in CD4 and major histocompatibility
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complex (MHC) class I downregulation, the stimulation of
virus infectivity and the alteration of the activation state of
cells.21 Moreover, Nef is essential for the maintenance of high
levels of viral replication and acquired immunodeficiency
syndrome (AIDS) pathogenesis in simian immunodeficiency virus (SIV)-infected macaques and has also been
shown to influence progression to AIDS in HIV-infected
individuals.22,23 These in vitro and in vivo observations suggest that Nef represents another possible attractive target for
the development of a multivalent therapeutic HIV vaccine.
However, p24 and Nef proteins have negative and positive charges, respectively, under physiological pH (pH 7.4)
precluding the use of either cationic or anionic NPs to bind
these two proteins together on the same particle. As an
alternative, Ni-NPs have roughly equal binding affinity to
his-tag proteins having similar sizes. Since both his-p24
and his-Nef have molecular weights of around 25–27 kDa,
they have the potential to be formulated in Ni-NPs and
co-delivered to dendritic cells.
HIV-1 Tat protein is an RNA binding transcriptional regulatory protein expressed early in HIV-1 infection, and necessary
for high level expression of viral proteins.10,11 Tat shows very
little variability and is highly conserved in the first exon among
the different subtypes, with the exception of the O subtype.24,25
Neutralization of Tat might prevent the transactivation of other
infected cells, and also prevent the neurotoxic properties. In
previous studies by our group, negatively-charged nanoparticles
were utilized to coat the positively-charged Tat (1–72 aa) on
the surface of the nanoparticles by charge interaction. Surface coated Tat (1–72 aa) led to significant enhancements in
antibody titer, Tat-neutralizing antibodies, and inhibition of
Tat-mediated long terminal repeat (LTR) transactivation versus
Alum-adjuvanted Tat.26 In addition, the nanoparticle vaccine
delivery system was shown to be dose-sparing.
In order to further investigate the utility of Ni-NPs for
vaccine formulation, we have extended previous studies of
Ni-NPs to include his-Tat antigen. In addition, we have compared the adjuvant activity and toxicity of Ni-NPs with the
previous reported ionic SDS/NPs. Finally, the co-delivery of
multiple antigens, p24 and Nef, using this platform vaccine
delivery system was also studied.

Materials and methods
Materials
Emulsifying wax (E-wax), comprised of cetyl alcohol and
polysorbate 60 in a molar ratio of 20:1, and aluminum hydroxide
were purchased from Spectrum (New Brunswick, NJ). PBS/
Tween 20 buffer, horseradish peroxidase (HRP), cetyltrimethyl
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ammonium bromide (CTAB), SDS and mannitol were purchased from Sigma Chemical Co. (St. Louis, MO). Alum
was purchased from Spectrum Chemicals and Laboratory
Products (Gardena, CA). Brij 78 was purchased from
Uniqema (New Castle, DE). 1,2-Dioleoyl-sn-Glycero-3[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl]
nickel and ammonium salt, abbreviated DOGS-NTA-Ni and
DOGS-NTA, respectively, were purchased from Avanti
Polar Lipids (Alabaster, AL). Goat anti-mouse immunoglobulin G (IgG) and peroxidase-linked species specific
F(ab′)2 fragment was purchased from Amersham Pharmacia
Biotech (Piscataway, NJ). Interferon-γ (IFN-γ) ELISA kit,
streptavidin horseradish peroxidase (Sv-HRP), fluorescein
isothiocyanate (FITC)-labeled anti-mouse CD11c antibody
and biotinylated rat anti-mouse IgG1 and IgG2a monoclonal
antibodies were from BD Biosciences Pharmingen (San
Diego, CA). Tetramethylbenzidine (TMB) Substrate Kit and
NHS-fluorescein were purchased from Pierce (Rockford,
IL). The antigens his-p24 (a.a. 133–363) and his-Nef (a.a.
3–190) were obtained from Bioclone Inc (San Diego,
CA) with purity of 90% by SDS-Page. NHS-fluorescein
and Zeba de-salting column were purchased from Pierce
Biotechnology (Rockford, IL).

Expression of his-Tat
Tat 1–72 cDNA was polymerase chain reaction (PCR)
amplified from HIV-1 strain HXB2 (from NIH AIDS
reagent repository), using primers 5′-TAGGATCCGCCACCATGGAGCCAGTAGATC-3′ (forward) and
5′-GCGAATTCTCATTGCTTTGATAGAGAAAC-3′
(backward), and inserted into pHAT10 vector (BD Biosciences, San Jose, CA) at BamH I/EcoR I sites. The sequence
containing both his-tag Tat and Tat was then PCR amplified for two rounds from the resulting pHAT-Tat plasmid
using primers 5′-CTGTTCCAGGGGCCCTTGAAGGATCATCTC-3′ (forward, for first round PCR), 5′-AGAATTCTGGAAGTTCTGTTCCAGGGGCCC-3′ (forward, for
second round PCR), and 5′-ACTCGAGTCATTGCTTTGATAGAGAAAC-3′ (backward, for both), and inserted
into pGEM-4T2 vector (GE Healthcare, Piscataway, NJ) at
EcoR I/Xho I sites. A new cleavage site for PreScission Protease (GE Healthcare) was also incorporated between GST
and his-tag sequence. The resulting pGET-his-Tat plasmid
was transformed into BL21-T1 competent cells. Expression
of the fusion protein was induced with 3 mM IPTG for four
hours. Cells were then harvested and extracted with lysis
buffer (1 × phosphate-buffered saline [PBS] with 100 µM
phenylmethanesulphonylfluoride [PMSF]). For his-tag Tat
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protein, the clarified cell extract was applied to a 5 ml GSTrap
Sepharose column (GE Healthcare). The column was washed
with 10 column volumes of PBS. The fusion protein bound
on the column was then digested with 80 units of PreScission
Protease overnight at 4 °C. His-tag Tat protein released from
the column by digestion was then collected and analyzed
by SDS-PAGE and western blot. The eluted fractions were
separated by 12.5% SDS-PAGE gel and immunoblotted with
anti-Tat antibody. The immunoreactive bands showed the
monomer (∼10 kDa) as well as multimers of Tat. Coomassie
bright blue (CBB) staining showed a similar pattern of protein
bands as the western blot.

Preparation of Ni-NPs and NTA-NPs
Ni-NPs were prepared as described previously with
slight modifications.13 Briefly, in a 7 ml glass vial, 4 mg
of emulsifying wax (the oil phase) and 7 mg (3 mM) of
Brij 78 (the surfactant) were added and then melted at
65 °C. To this vial, 21.2 ml (0.1 mM) of DOGS-NTA-Ni
(10 mg/ml stock in chloroform) was added and the chloroform was evaporated on a hot plate (65 °C) while stirring.
De-ionized, 0.2 micron-filtered water (100 µl) was added to
the vial at 65 °C and the contents of the vial were mixed on
the hot plate for 2 min to form a slurry-like mixture. Then,
1.9 ml water was added to the mixture at 65 °C to form clear
oil-in-water microemulsions. NPs were obtained by cooling
the vials to room temperature while stirring. NPs of similar composition but without Ni were prepared in the same
manner using 0.1 mM of DOGS-NTA lipid instead, referred
to as NTA-NPs. Excess DOGS-NTA-Ni or DOGS-NTA
was separated from the Ni-NPs by using a gravity packed
Sepharose CL4B gel permeation chromatography (GPC)
column (15 × 70 mm). Briefly, 200 µl of the Ni-NPs was
passed down the GPC column using PBS, pH 7.4 as the
mobile phase. Fractions (1 ml) were collected and the
fractions containing the NPs (as determined by measuring
the particle size intensity with the particle sizer) were stored
at 4 °C for further in vivo and in vitro study. The NPs were
characterized by measuring their size, using a Coulter N5
Submicron Particle Sizer (Coulter Corporation, Miami, FL)
at 90°, and charge, using a Malvern Zeta Sizer 2000 (Malvern
Instruments, Southborough, MA).

Preparation of fluorescence-labeled
his-tag Tat protein (fluo-his-Tat)
and binding of fluo-his-Tat to Ni-NPs
Fluo-his-Tat was prepared using NHS-fluorescein, which
is an amine-reactive derivative of fluorescein dye. Briefly,
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NHS-fluorescein (1 mg) was dissolved in 1000 µl DMSO,
and 13 µl of this solution was added to 300 µg his-Tat protein
dissolved in 300 µl PBS buffer. The reaction was performed
at room temperature for one hour in the dark. Unreacted
NHS-fluorescein was removed using a Zeba de-salting
column. The degree of modification was calculated using the
fluorescein molar extinction coefficient = 68,000 M-1 cm-1
and the method provided by the vendor. Fluo-his-Tat was
stored at -80 °C until use. To determine the optimal binding
ratios, fluo-his-Tat was mixed with the GPC column-purified
Ni-NPs at a 1:20, 30, 40, 50, 60 w/w ratios in PBS, pH 7.4
at 4 °C overnight. Free protein was separated from NP
bound protein by passing the fluo-his-Tat and NP mixtures
through the Sepharose CL4B column using PBS, pH 7.4 as
the mobile phase. Fractions collected (1 ml) were analyzed
by fluorescence to determine the percent of his-Tat bound
to Ni-NPs.

Preparation of anionic SDS/NPs
and cationic CTAB/NPs
Cationic and anionic NPs from oil-in-water microemulsion
precursors were prepared as previously described with
slight modification. 10,11 Briefly, 2 mg of emulsifying
wax and 3.5 mg of Brij 78 was melted and mixed
at ∼65 °C. Deionized water (980 µl) was added to the
melted wax and surfactant while stirring to form an
opaque suspension. Finally, 20 µl of CTAB (50 mM) or
SDS (50 mM) was added to form clear microemulsions
at 60–65 °C. The microemulsions were cooled to room
temperature while stirring to obtain NPs (2 mg/ml). The
final concentration of components in the NP suspension
was E-wax (2 mg/ml), Brij 78 (3 mM), and either 1 mM
SDS (for anionic SDS/NPs) or 1 mM CTAB (for cationic
CTAB/NPs).

Mouse immunization study
using his-Tat/Ni-NP
Female BALB/c mice (8–10 weeks old) obtained from
Charles River Laboratories (Indianapolis, IN) were immunized subcutaneously with 150 µl of the formulations.
Mice (n = 8/group) were dosed on day 0 and day 14 with
his-Tat/Ni-NP, his-Tat/NTA-NP, his-Tat/SDS/NP, or his-Tat
adjuvanted with Alum. The Tat doses in every group were
kept as 1.5 µg per mouse and E-wax for preparation of NP
or Alum was kept as 100 µg. On day 28, mice were bled by
cardiac puncture and sera were separated. All sera collected
were stored at −20 °C for further characterization.
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Determination of anti-Tat, p24
and Nef antibody titers
Antigen-(Tat, p24 or Nef) specific serum IgG, IgG1 and
IgG2a antibody titers were determined by ELISA. Briefly,
96-well plates (Costar) were coated with 100 µl of recombinant Tat, his-p24 or his-Nef (10 µg/ml in 0.01 M carbonate
buffer, pH 9.6) overnight at 4 °C. The plates were blocked
for one hour at 37 °C with 200 µl of 2% BSA prepared
in PBS/Tween 20. The plates were then incubated with
100 µl per well of mouse serum diluted appropriately in
2% BSA/PBS/Tween 20 for two hours at 37 °C. The plates
were washed with PBS/Tween 20 and incubated with
100 µl/well sheep-anti-mouse IgG HRP (1:5000 in 2%
BSA/PBS/Tween 20) for one hour at 37 °C. For IgG1 and
IgG2a determination, the plates were similarly incubated with
goat anti-mouse IgG1-HRP or goat anti-mouse IgG2a-HRP
diluted 1:5000 (2% BSA/PBS/Tween 20). After washing the
plates with PBS/Tween 20, plates were developed by adding
80 µl of TMB substrate and incubating for 10 min at RT. The
color development was stopped by the addition of 50 µl of
2M H2SO4 and the OD at 450 nm was read using a Bio-Tek
Synergy 2 Microplate Reader (Bio-Tek Instruments, Inc.).
The endpoint titer was defined as the highest reciprocal dilution of sera yielding an OD450 value at least 3 × background
obtained using samples obtained from naïve mice.

Cytokine release assay
from Tat stimulated splenocytes
Mice were sacrificed on day 28 and spleen cells were isolated.
Red blood cells were lysed by adding 1 × ammonium
chloride/potassium carbonate (ACK) buffer (156 mM
NH4Cl, 10 mM KHCO3 and 100 µM EDTA) and incubating
for 1–2 min at RT. The cells were spun down at 1,500 rpm,
4 °C for 10 min. The cells were resuspended in RPMI 1640
(supplemented with 10% heat-inactivated fetal calf serum,
1 mM HEPES, 2 µM l-glutamine, 10 U/ml penicillin,
100 U/ml streptomycin, 50 µM 2-mercaptoethanol).
To measure cytokine release from stimulated splenocytes,
parallel 48-well plates were set up using 1 × 106 cells/well
(total volume of 400 µl) and incubated with media alone or
Tat (5 µg/ml) at 37 °C, 5% CO2 for 72 hours. The supernatants were collected at 72 hours and stored at −80 °C for
IFN-γ analysis by ELISA (BD Biosciences).

NP toxicity to dendritic cells
DC2.4 cells were obtained from bone marrow cells infected
with a retrovirus encoding myc and raf by using supernatant
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from NIH J2 Leuk cells, as previously described.27 DC2.4
cells were provided by Dr. Leaf Huang at the University of
North Carolina at Chapel Hill. After incubation of DC2.4
cells with NPs, the cells were stained with CD11c and propidium iodide and analyzed by flow cytometry. The percentage
of cell death of DC was determined by the proportion of
PI+ cells within the CD11c+ region using a BD FACSCanto
digital flow cytometer (BD Biosciences).

Preparation of his-p24/his-Nef/Ni-NP
formulation and in vivo immunization
study
Ni-NPs were prepared as described above. Since the molecular weights of p24 and Nef are similar (about 24–27 kDa), the
previous published optimal P : L weight ratio (1:33.3 w/w) for
his-p24 was used for preparation of the formulation his-p24/
his-Nef /Ni-NPs.13 Briefly, his-p24 and his-Nef were bound
to Ni-NPs at the weight ratio of 1.5:1.5:100 (his-p24:his-Nef:
Ni-NPs) in PBS at 4 °C overnight. The same weight ratio
of proteins to Alum was used to prepare the Alum/his-p24/
his-Nef formulation. Single antigen formulations his-p24/
Ni-NP and his-Nef/Ni-NP were prepared at the weight ratio
of 1:33.3 w/w. Blank NPs without DOGS-NTA-Ni were
added to the his-p24/Ni-NP and his-Nef/Ni-NP to retain
the same amount of NPs among all the formulations. Female
BALB/c mice (8–10 weeks old) were immunized subcutaneously with 150 µl of the formulations. Mice (n = 8/group)
were dosed on day 0 and day14 with 1.5 µg his-p24 and/or
his-Nef per mouse. The mice were bled by cardiac puncture
on day 28 and the sera were separated and stored at -20 °C
for antigen-specific IgG analysis by ELISA.

Statistical analysis
The data were analyzed using Prism 3.0 (GraphPad Software,
La Jolla, CA). A one-way ANOVA analysis was performed
first followed by the Tukey’s test for multiple comparisons.
Data were concluded to be statistically different if p  0.05.

Results and discussion
Optimization and characterization
of his-Tat/Ni-NP formulations using
fluorescent labeled his-Tat
We reported previously on the use of lipid-based NPs with
a small amount of Ni-NPs to deliver his-p24 antigen.13
To test if this system is suitable to deliver other HIV antigens such as cationic Tat, his-Tat was bound to the surface
of Ni-NPs. Fluorescent-labeled his-Tat was prepared and

HIV/AIDS - Research and Palliative Care 2009:1

Nickel nanoparticles for HIV antigen delivery

used to optimize and characterize the formulation. To avoid
the over-modification of his-Tat by fluorescein, a 1:1 molar
ratio of protein to NHS-fluorescein was used in the labeling
reaction. This reaction yielded fluorescein-his-Tat with a
degree of modification of ∼10%.
The elution profile of fluorescein-labeled his-Tat mixed
with Ni-NPs at five different weight ratios is shown in
Figure 1. NPs eluting in fractions 3–6 were monitored by
light-scattering intensity (not shown) and free protein was
detected in fractions 8–12 and quantified by fluorescence
intensity (y-axis). The broadening of the peaks in fractions
3–6 with increasing his-Tat/Ni-NP ratios correspond directly
to the amount of Ni-NPs that were loaded onto the column.
At a 1:60 w/w ratio of his-Tat to Ni-NPs (P:L), the fluorescence intensity of free his-Tat (fraction 10) was very low
while the NP bound his-Tat (fraction 4) was the highest,
suggesting the majority of the protein was associated with
NP at this ratio. The his-Tat binding to Ni-NPs was found
to be stable for four hours in PBS at 37 °C, pH 7.4 with less
than 10% of the protein released and particle sizes retained at
approximately 120 nm over the time frame (data not shown).
Therefore, the ratio of P:L close to 1:60 (w/w) was used
for the in vivo studies. The optimal P:L ratio for his-Tat is
different from a previous report of his-p24.13

In vivo immunization using optimized
his-Tat/Ni-NP formulations
Based on the optimization studies assessing the fluorescence
labeled his-Tat binding to Ni-NPs study, his-Tat was bound
to Ni-NPs at a 1:60 w/w ratio for the in vivo immunization studies. The binding of his-Tat to the Ni-NPs was also
confirmed by SDS-PAGE (data not shown). The use of
DOGS-NTA entrapped in NPs was also investigated to control for non-specific adsorption of the protein on the surface
of the NPs. The carboxylic groups of the NTA provide an
overall slightly net-negative charge to the surface of the NPs
and could allow his-Tat, a cationic protein, to be coated on
the surface of the particles. The strong negatively-charged
NPs made using SDS as a surfactant was used as a positive
control.11 As shown in Figure 2A, the Ni-NPs resulted in
significant enhancement in antibody responses compared
to both Alum and NTA-NPs (p  0.05). However, the total
Tat-specific IgG titer for the Ni-NPs and SDS/NPs was
comparable. In this study, the primary binding of protein on
NPs is mediated through the interaction of the N-terminal
his-tag to Ni on the surface of NPs. Therefore, it is possible
that this binding may lead to an orientation of the protein
that is different than when the same protein is adsorbed
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Figure 1 Binding of fluo-his-Tat to Ni-NPs.The GPC purification profile for fluo-his-Tat bound to Ni-NPs at 1:20, 30, 40, 50, 60 w/w ratio of protein to Ni-NPs. Ni-NPs eluted
in fraction 3–6 as determined by particle size intensity (not shown).The extent of his-Tat bound to Ni-NPs was determined by separating Ni-NP bound protein (fractions 3–6)
from free protein, which elutes in faction 8–12 as determined by fluorescence intensity measurements.
Abbreviations: GPC, gel permeation chromatography; NPs, nanoparticles.

onto SDS-NPs or adjuvanted with Alum thereby resulting
in qualitative differences in the induced immune responses.
In fact, in previous studies we have shown by epitope mapping that Tat adsorbed on SDS-NPs led to differences in
immune responses to several different peptide regions on
Tat as compared to Tat adjuvanted with Alum.10
It is known that during an immune response, the release of
Th1 or Th2 cytokines will affect the production of antibody
isotypes. Th1 cytokines like IFN-γ promote class switching
to the IgG2a isotype. BALB/c mice bias the immune response
towards a Th2 profile, resulting in a relative lack of IFN-γ and
more antibodies of IgG1 isotype. The serum isotype levels,
IgG1 versus IgG2a, were measured to assess the type of
immune response generated (ie, Th1 or Th2). The isotype
analysis in these studies revealed that the Ni-NPs resulted
in higher levels of IgG2a compared to the Alum group
(p  0.01), while the IgG1 levels were comparable to the
other three immunized groups (Figure 2B). The data indicated that all the NP groups (Ni-NP, NTA-NP and SDS/NP)
showed a balanced IgG2a/IgG1 ratio of approximately 0.5.
In contrast, the IgG2a/IgG1 ratio in the Alum group was
0.153 indicating a more Th2-biased response.
The cellular immune responses in these studies were
evaluated by IFN-γ release assays. Splenocytes from immunized mice that were stimulated in vitro with recombinant
Tat protein demonstrated significantly higher IFN-γ release
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than those from naive mice. Moreover, the IFN-γ release
from stimulated splenocytes of Ni-NP immunized mice was
significantly higher than that from the Alum and NTA-NPs
groups (Figure 3). Although Ni-NPs showed superior adjuvant activity than Alum and NTA-NPs, it had comparable
activity with the previously developed SDS/NPs. Thus,
although the different NP types induced similar Th1/Th2
profiles inferred by antibody isotype differences, Ni-NP
and SDS/NP induced a higher Th1 response inferred by
IFN-γ release from spleen cells. This may reflect a greater
stimulation of CD8 T cells by the Ni-NPs and SDS/NP
which might not contribute to antibody isotype switching
in vivo.

Dendritic cell toxicity induced by NPs
The immunization results above showed that the Ni-NP
vaccine delivery system was suitable for his-Tat delivery
and generated enhanced immune responses versus Alum
adjuvant, but comparable to that of the previously developed SDS/NPs. However, we have previously noted that
the highly anionic SDS NPs showed a dose-dependent toxic
effect on bone marrow-derived macrophages (Woodward
and Mumper, unpublished results). To ascertain potential
differences in the toxicity of the various NPs used in
these studies, the toxicity of Ni-NPs, NTA-NPs, SDS/NPs
(anionic) and CTAB/NPs (cationic) were investigated
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Figure 2 Tat-specific serum IgG titer. BALB/c mice were immunized on day 0 and day 14 with 150 µl of each formulation containing 1.5 µg his-Tat and 100 µg NPs or Alum.
(A) Tat-specific total serum IgG titers were evaluated on Day 28 by ELISA. Data represent the mean ± S.D. *p  0.05 compared to NTA and Alum groups. (B) Tat-specific
serum IgG2a and IgG1 titer were evaluated on day 28 by ELISA. The mean IgG2a/IgG1 ratio is indicated on the bottom of the graphed titer for each group. Data represent
the mean ± S.D. **p  0.01 compared to Alum group.
Abbreviations: IgG, immunoglobulin G; NTA, nitrilotriacetic acid; NPs, nanoparticles.
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Figure 3 Cellular responses to his-Tat. Mice were immunized with 1.5 µg of his-Tat on day 0 and day 14. Spleens were harvested and pooled for each group on day 28. Cells
(1 × 106) were stimulated with recombinant Tat (5 µg/ml) and the supernatants were evaluated for IFN-γ release at 72 h by ELISA. The data represent the mean ± SD (n = 3).
*p  0.05 compared to the Alum and NTA groups.
Abbreviations: NTA, nitrilotriacetic acid; NPs, nanoparticle; IFN-g , interferon-g ; SD, standard deviation; SDS, sodium dodecyl sulfate.

in the DC2.4 dendritic cell line. All the formulations
showed low toxicity for 24-hour treatment (around 5%
PI-positive cells). However, after 48-hour treatment, the
charged NP (SDS/NPs and CTAB/NPs)-treated DC2.4
cells showed more than 20% PI-positive (dead) cells. Both
NTA-NPs and Ni-NPs showed less toxicity than either

of the charged NPs (p  0.05 compared to SDS/NPs,
p  0.01 compared to CTAB/NPs) (Figure 4). The data also
showed that positive charged CTAB/NPs were more toxic
than negative-charged SDS/NPs (p  0.05) (Figure 4).
Thus, Ni-NPs may be superior to charged NP in terms of
safety/toxicity.
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Figure 4 Cytotoxicity induced by NPs in DC2.4 cells. DC2.4 cells were incubated with NPs (11 µg/ml) for the indicated time. The cells were washed and incubated with FITC
labeled CD11c and PI. The percentage of cell death was determined by the proportion of PI+ cells within the CD11c+ region. The data represent the mean ± SD (n = 5).
Notes: *p  0.05 compared to NTA-NPs, Ni-NPs and CTAB-NPs; **p  0.01 compared to NTA-NPs and Ni-NPs.
Abbreviations: PI, propidium iodine; CTAB, cetyltrimethyl ammonium bromide; NPs, nanoparticles; FITC, fluorescein isothiocyanate.
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Ni-NPs for the delivery
of multiple antigens
Although negatively-charged SDS/NPs are suitable for the
delivery of Tat and other cationic antigens, they are obviously
not suitable for multiple antigens especially if the antigens are
negatively-charged. The toxicity study in DC2.4 cells also
showed that the charged NP may not be warranted for larger
antigen doses. An alternative strategy would be to utilize
Ni-NPs to bind various his-tagged proteins irrespective of their
native charge. To test this hypothesis, the his-tagged antigens,
gag p24 and Nef, were bound to Ni-NPs. Indeed, mice
co-immunized with his-p24 and his-Nef antigens co-bound
to Ni-NPs, had higher p24-specific antibodies as compared

Gag p24-specific serum IgG
OD @ 450 nm

A

to mice immunized with p24-alone bound to NPs (p  0.05).
In addition, his-p24/his-Nef/Ni-NP resulted in significant
enhancement in p24-specific antibody response compared to
his-p24/his-Nef adjuvanted with Alum (p  0.05) (Figure 5A).
In a similar manner, mice immunized with his-p24/his-Nef/
Ni-NP had greater Nef-specific antibodies than mice immunized with Nef alone bound to NPs (Figure 5B). Thus, Ni-NPs
provide a distinct advantage of allowing the binding of varied
his-tagged proteins, regardless of charge.
In these current studies, Ni-NPs were successfully
used for the delivery of cationic his-Tat antigen to induce
enhanced immune responses compared to Alum. Although
this system did not show superior adjuvant activity compared
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Figure 5 Ni-NPs for co-delivery of his-tagged p24 and Nef antigens. BALB/c mice were immunized on day 0 and day 14 with 150 µl of each formulation containing 1.5 µg
his-p24 and/or 1.5 µg his-Nef adjuvanted by 100 µg NPs or Alum. Total serum IgG levels at day 28 were diluted 100, 1,000 and 10,000-fold and measured by ELISA. A) Gag
p24-specific serum IgG titer. *p  0.05 compared to Alum/his-p24/his-Nef and his-p24/Ni-NP groups. B) Nef-specific serum IgG titer, *p  0.05 compared to his-Nef/Ni-NP
group. Data represent the mean ± SD.
Abbreviations: IgG, immunoglobulin G; NPs, nanoparticles; SD, standard deviation.
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to SDS/NPs, it showed less toxicity to dendritic cells than
SDS/NPs. Interestingly, cationic CTAB/NPs were more
toxic to dendritic cells than anionic SDS/NPs. Dendritic
cells play a central role to link the innate immune responses
to adaptive immune responses, so their life-span affects the
potency of vaccines. For example, it was reported that a
high dose of cationic liposome induced apoptosis of dendritic cells leading to compromised immune responses.28
In addition, two other reports showed that the potency of a
dendritic cell-based vaccine was enhanced by incorporating
anti-apoptotic strategies for prolonging dendritic cell life.29,30
Therefore, utilizing less toxic but equally effective vaccine
carriers such as Ni-NPs to bind his-tagged protein antigens
have potential advantages.

Conclusions
We have expanded our studies of Ni-NPs as an effective
vaccine delivery vehicle to include the delivery of cationic
his-Tat antigen, and the co-delivery of gag p24 and Nef.
Ni-NPs induced enhanced Tat-specific immune responses
compared to Alum. Although this system did not show superior adjuvant activity compared to SDS/NPs, it showed less
toxicity to dendritic cells than SDS/NPs. Ni-NPs were found to
be suitable for the co-delivery of p24 and Nef protein antigens,
and the binding of various his-tagged antigens on the same
particle is regardless of the charge. The safety and adjuvant
activity of Ni-NPs make this system suitable for HIV vaccine
development, especially for multivalent vaccines.
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